• Ambrisentan (Par Pharmaceutical)
Ambrisentan film-coated tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). It is supplied in 5 mg and 10 mg tablet strengths and is available in the following package configurations: 5 mg 10 count bottle, 5 mg 30 count bottle, 10 mg 10 count bottle and 10 mg 30 count bottle.
For more information about Ambrisentan, log in to biosupply.fffenterprises.com
• Bosentan (Par Pharmaceutical)
Bosentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%). It is available as a 62.5 mg tablet in a bottle containing 60 tablets and a 125 mg tablet in a bottle containing 60 tablets.
For more information about Bosentan, log in to biosupply.fffenterprises.com
• Treprostinil (Par Pharmaceutical)
Treprostinil injection is a prostacyclin vasodilator indicated for pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension in patients requiring transition from epoprostenol. It is supplied in 20 mL multidose vials as sterile solutions in water for injection, individually packaged in cartons, and is available in 1 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL concentrations.
For more information about Treprostinil, log in to biosupply.fffenterprises.com
• KOATE (Kedrion)
KOATE is indicated for the treatment of hemophilia A in which there is a demonstrated deficiency of activity of clotting factor VIII. Koate provides a means of temporarily replacing the missing clotting factor to control or prevent bleeding episodes, or to perform emergency and elective surgery on individuals with hemophilia. It is supplied in a kit containing one single-use vial of Koate lyophilized powder, one vial of sterile water for injection, USP, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set.
For more information about KOATE, log in to biosupply.fffenterprises.com
• ELCYS (EXELA PHARMA SCIENCES)
ELCYS (cysteine hydrochloride injection) is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN) and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. Each 10 mL of ELCYS contains 500 mg of cysteine hydrochloride, USP (equivalent to 345 mg of cysteine) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH range from 1.0 to 2.5.
For more information about ELCYS, log in to biosupply.fffenterprises.com
These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.
|
